# Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

> **NCT02773797** · PHASE4 · WITHDRAWN · sponsor: **Dayton VA Medical Center**

## Conditions studied

- COPD

## Interventions

- **DRUG:** IN-DEX 1.0 mcg/kg, intranasal saline
- **DRUG:** IN-DEX 1.5 mcg/kg, intranasal saline
- **DRUG:** Placebo - Saline

## Key facts

- **NCT ID:** NCT02773797
- **Lead sponsor:** Dayton VA Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08
- **Primary completion:** 2017-07
- **Final completion:** 2018-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773797, "Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02773797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*